Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04529005
Other study ID # 2020-0526
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date August 13, 2020
Est. completion date August 1, 2021

Study information

Verified date November 2022
Source University of Illinois at Chicago
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The current standard of catecholamine vasopressor management of perioperative hypotension in kidney transplant patients carries significant risks and falls short in many ways. Currently, there is an absence in the scientific literature and research describing the hemodynamic effectiveness and safety of novel pharmacologic agents such as angiotensin II (Giapreza - Ang II) in perioperative kidney transplant patients. Phase 3 registration trials have demonstrated the superior safety and efficacy of Ang II (Giapreza) in distributive shock patients compared to traditional vasopressor agents and the novel mechanism of action may provide additional protection in renal transplant patients. The pilot study entails giving informed and consenting kidney transplant recipients Ang II (Giapreza) as their first vasopressor if the need for vasopressors emerge either intraoperatively or postoperatively in kidney transplant recipients. The primary objective is to evaluate the safety and hemodynamic effects of Ang II (Giapreza) in the renal transplant population.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date August 1, 2021
Est. primary completion date August 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult patients > 18 years of age - Receiving deceased donor kidney transplant - Pre-transplant Ejection Fraction (within past 18 months) > 50% - Intraoperative or postoperative distributive shock (according to hospital and study protocol) requiring vasopressor support Exclusion Criteria: - Pregnant patients (they would be excluded from receiving a transplant) - Prisoners - History of mesenteric ischemia - History of aortic dissection - History of abdominal aortic aneurysm - Allergy to mannitol - Absolute neutrophil count < 1000 cell/mm3 (within past 18 months) - Diagnosis of Raynaud's phenomenon, systemic sclerosis or vasospastic disease

Study Design


Intervention

Drug:
Angiotensin II
If intraoperative or postoperative hypotension occurs (e.g. SBP < 120 mmHg) and the attending surgeon and/or attending anesthesiologist deems vasopressor therapy to be necessary, angiotensin II (Giapreza) will be the first vasopressor used for management.

Locations

Country Name City State
United States University of Illinois Hospital and Health Sciences System Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
University of Illinois at Chicago La Jolla Pharmaceutical Company

Country where clinical trial is conducted

United States, 

References & Publications (12)

Aulakh NK, Garg K, Bose A, Aulakh BS, Chahal HS, Aulakh GS. Influence of hemodynamics and intra-operative hydration on biochemical outcome of renal transplant recipients. J Anaesthesiol Clin Pharmacol. 2015 Apr-Jun;31(2):174-9. doi: 10.4103/0970-9185.155144. — View Citation

Busse LW, Ostermann M. Vasopressor Therapy and Blood Pressure Management in the Setting of Acute Kidney Injury. Semin Nephrol. 2019 Sep;39(5):462-472. doi: 10.1016/j.semnephrol.2019.06.006. — View Citation

Campos L, Parada B, Furriel F, Castelo D, Moreira P, Mota A. Do intraoperative hemodynamic factors of the recipient influence renal graft function? Transplant Proc. 2012 Jul-Aug;44(6):1800-3. doi: 10.1016/j.transproceed.2012.05.042. — View Citation

Choi JM, Jo JY, Baik JW, Kim S, Kim CS, Jeong SM. Risk factors and outcomes associated with a higher use of inotropes in kidney transplant recipients. Medicine (Baltimore). 2017 Jan;96(1):e5820. doi: 10.1097/MD.0000000000005820. — View Citation

Ciapetti M, di Valvasone S, di Filippo A, Cecchi A, Bonizzoli M, Peris A. Low-dose dopamine in kidney transplantation. Transplant Proc. 2009 Dec;41(10):4165-8. doi: 10.1016/j.transproceed.2009.08.058. — View Citation

Day KM, Beckman RM, Machan JT, Morrissey PE. Efficacy and safety of phenylephrine in the management of low systolic blood pressure after renal transplantation. J Am Coll Surg. 2014 Jun;218(6):1207-13. doi: 10.1016/j.jamcollsurg.2014.01.058. Epub 2014 Mar 12. — View Citation

Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hastbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM; ATHOS-3 Investigators. Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoa1704154. Epub 2017 May 21. — View Citation

Lankadeva YR, Kosaka J, Evans RG, Bellomo R, May CN. Urinary Oxygenation as a Surrogate Measure of Medullary Oxygenation During Angiotensin II Therapy in Septic Acute Kidney Injury. Crit Care Med. 2018 Jan;46(1):e41-e48. doi: 10.1097/CCM.0000000000002797. — View Citation

Robert R, Guilhot J, Pinsard M, Longeard PL, Jacob JP, Gissot V, Hauet T, Seguin F. A pair analysis of the delayed graft function in kidney recipient: the critical role of the donor. J Crit Care. 2010 Dec;25(4):582-90. doi: 10.1016/j.jcrc.2010.02.011. Epub 2010 Apr 8. — View Citation

Toth M, Reti V, Gondos T. Effect of recipients' peri-operative parameters on the outcome of kidney transplantation. Clin Transplant. 1998 Dec;12(6):511-7. — View Citation

Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR, Kashani K, Szerlip HM, Prowle JR, Bihorac A, Finkel KW, Zarbock A, Forni LG, Lynch SJ, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Bellomo R; Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Investigators. Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. Crit Care Med. 2018 Jun;46(6):949-957. doi: 10.1097/CCM.0000000000003092. Erratum In: Crit Care Med. 2018 Aug;46(8):e824. — View Citation

Walsh M, Devereaux PJ, Garg AX, Kurz A, Turan A, Rodseth RN, Cywinski J, Thabane L, Sessler DI. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology. 2013 Sep;119(3):507-15. doi: 10.1097/ALN.0b013e3182a10e26. — View Citation

* Note: There are 12 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Duration of ATII Vasopressor Usage in the Intraoperative Setting Duration of vasopressor usage while in the operating room measured in hours of usage presented as median and IQR. Duration of usage during the transplant surgery - presented in hours
Secondary Number (and Percentage) of Patients With Arrhythmias The presence of arrhythmia was confirmed via EKG, flowsheet, or note documentation from the electronic medical record. From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
Secondary Number (and Percentage) of Patients With Peripheral/Visceral Ischemia The presence of digital or other peripheral/visceral ischemia was captured from reviewing chart documentation for each patient. From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
Secondary Number (and Percentage) of Patients With Thrombosis Incidence of venous or arterial thrombosis occurring during the hospitalization for kidney transplant (captured by ultrasound or other diagnostic imaging) From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
Secondary Number (and Percentage) of Patients With Fungal Infections The presence of post-operative fungal infections were captured prior to discharge as documented by the clinical care team in the electronic medical record. From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
Secondary Number (and Percentage) of Patients With Hyperglycemia The presence of hyperglycemia was captured for each patient and was determined by those patients requiring the use of an insulin infusion after their transplant surgery. From date and time of study drug initiation during or after transplant operation until study drug is discontinued up to a maximum of 30 days.
Secondary Number (and Percentage) of Patients With Delayed Graft Function The presence of Delayed Graft Function was captured for each patient and defined by the need for renal replacement therapy up to 7 days post-operative. From post-op to 7 days post-op
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05898126 - Renin-guided Hemodynamic Management in Patients With Shock N/A
Completed NCT05563701 - Evaluation of the LVivo Image Quality Scoring (IQS)
Recruiting NCT05066256 - LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock N/A
Not yet recruiting NCT06285513 - Cardiovascular Metabolic Remodeling in Shock
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Terminated NCT02755155 - Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients Phase 4
Not yet recruiting NCT01941472 - Transcutaneous pO2, Transcutaneous pCO2 and Central Venous pO2 Variations to Predict Fluid Responsiveness N/A
Terminated NCT01696175 - PICU Admission Lactate and Central Venous Oxymetry Study N/A
Completed NCT01680783 - Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure N/A
Recruiting NCT01174966 - Assessment of Transcutaneous Oxygen Tension/Oxygen Challenge Test in Intensive Care Unit (ICU) Patients N/A
Recruiting NCT01157299 - Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO N/A
Completed NCT00743522 - Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication
Completed NCT03296891 - Point of Care Ultrasonography In The Management of Shock: A Pilot Study N/A
Recruiting NCT05922982 - Norepinephrine Weaning Guided by the Hypotension Prediction Index in Vasoplegic Shock After Cardiac Surgery N/A
Withdrawn NCT04705701 - Comparing Post Cardiac Surgery Outcomes in ESRD Patient's With Early Dialysis Versus Standard Care N/A
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Completed NCT05330676 - Evaluation of Microcirculatory Function and Mitochondrial Respiration After Cardiovascular Surgery
Active, not recruiting NCT04079829 - Postoperative Respiratory Abnormalities
Completed NCT04089098 - VOLume and Vasopressor Therapy in Patients With Hemodynamic instAbility
Completed NCT03190408 - Variation in Fluids Administered in Shock